News about Market

Sanofi to Acquire Dynavax, Expanding Vaccine Portfolio

Sanofi has agreed to acquire Dynavax, strengthening its adult immunisation portfolio with an approved hepatitis B vaccine and a shingles vaccine candidate in phase I/II development. The deal combines Dynavax’s vaccine assets with Sanofi’s global development and commercial capabilities.

Market | 24/12/2025 | By News Bureau |  147

Vaccinex Secures USD 60 Million Financing for Phase IIb Alzheimer's Trial

Vaccinex Inc has entered into a USD 60 million revenue-sharing agreement with Pepinemab Development Venture (PDV), LP to finance an expanded Phase IIb clinical trial of its anti-SEMA4D antibody, pepinemab, for the treatment of Alzheimer’s disease.

Market | 24/12/2025 | By News Bureau |  126

Zydus Partners with Bioeq for US Commercialisation of Lucentis Biosimilar

Zydus has entered into a partnership with Bioeq to commercialise NUFYMCO, an interchangeable biosimilar to Lucentis, in the US market. Under the agreement, Bioeq will handle development, manufacturing, regulatory approval and product supply, while Zydus will oversee US commercialisation.

Market | 24/12/2025 | By News Bureau |  161

Biofabri and Bharat Biotech Sign Technology Transfer Deal for MTBVAC

Biofabri and Bharat Biotech have entered into a technology transfer agreement to enable end-to-end manufacturing of the MTBVAC tuberculosis vaccine candidate, supporting global efforts to expand access to new TB prevention options, particularly in high-burden, low- and middle-income countries.

Market | 24/12/2025 | By News Bureau |  193

Biocon Biologics Secures Global Rights to Hulio

The new agreement supersedes the existing collaboration agreement between Biocon Biologics and Fujifilm Kyowa Kirin Biologics (FKB) for biosimilar Adalimumab, under which Biocon Biologics only had commercialisation rights.

Market | 23/12/2025 | By News Bureau |  185

Glenmark Launches Epinephrine Injection Multi-Dose Vial

Glenmark has introduced its Epinephrine Injection USP, 1?mg/mL, 30?mg/30?mL multiple-dose vial, which is bioequivalent and therapeutically equivalent to the reference drug by BPI Labs, LLC (NDA 205029), offering a reliable alternative for patients and healthcare providers.

Market | 23/12/2025 | By News Bureau |  169

Rectify and Boehringer Ingelheim Collaborate to Advance First-in-class CKD Treatments

The collaboration will focus on accelerating the development of first-in-class oral small-molecule therapies for chronic kidney disease and other conditions, leveraging Rectify’s ABCC6-targeting platform designed to reduce pathological calcification.

Market | 23/12/2025 | By News Bureau |  119

Alvotech Announces European Launch of Golimumab Biosimilar via Advanz Pharma

Alvotech has announced the European launch of AVT05, the first biosimilar to Simponi (golimumab), through its partner Advanz Pharma, following a tender award from NHS England in the UK to support market introduction.

Market | 22/12/2025 | By News Bureau |  120

Emcure Launches Poviztra to Broaden Access to Weight Management Therapy

Emcure has launched Poviztra, a once-weekly weight management therapy available in a pen device across five dosage strengths, with prices starting at INR 8,790 per month, aimed at improving access through convenient and precise dosing.

Market | 22/12/2025 | By News Bureau |  310

Samsung Biologics Expands US Manufacturing with HGS Acquisition from GSK

Samsung Biologics has acquired Human Genome Sciences (HGS) from GSK, securing its first US-based manufacturing site and strengthening its global supply network. The company plans further investments to expand capacity and capabilities at the facility, reinforcing its long-term commitment to the US biopharmaceutical manufacturing ecosystem.

Market | 22/12/2025 | By News Bureau |  282